Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, NIH, DHHS, Frederick, Maryland, USA.
Hum Mutat. 2022 Oct;43(10):1396-1407. doi: 10.1002/humu.24427. Epub 2022 Jul 12.
Chordoma is a rare bone tumor with genetic risk factors largely unknown. We conducted a whole-exome sequencing (WES) analysis of germline DNA from 19 familial chordoma cases in five pedigrees and 137 sporadic chordoma patients and identified 17 rare germline variants in PALB2 and BRCA2, whose products play essential roles in homologous recombination (HR) and tumor suppression. One PALB2 variant showed disease cosegregation in a family with four affected people or obligate gene carrier. Chordoma cases had a significantly increased burden of rare variants in both genes when compared to population-based controls. Four of the six PALB2 variants identified from chordoma patients modestly affected HR function and three of the 11 BRCA2 variants caused loss of function in experimental assays. These results, together with previous reports of abnormal morphology and Brachyury expression of the notochord in Palb2 knockout mouse embryos and genomic signatures associated with HR defect and HR gene mutations in advanced chordomas, suggest that germline mutations in PALB2 and BRCA2 may increase chordoma susceptibility. Our data shed light on the etiology of chordoma and support the previous finding that PARP-1 inhibitors may be a potential therapy for some chordoma patients.
软骨肉瘤是一种罕见的骨肿瘤,其遗传风险因素在很大程度上尚不清楚。我们对五个家系的 19 例家族性软骨肉瘤病例和 137 例散发性软骨肉瘤患者的胚系 DNA 进行了全外显子组测序(WES)分析,在 PALB2 和 BRCA2 中鉴定出 17 种罕见的胚系变异,其产物在同源重组(HR)和肿瘤抑制中发挥重要作用。一个 PALB2 变异在一个有四个受影响的人或强制性基因携带者的家庭中与疾病共分离。与基于人群的对照相比,软骨肉瘤病例在这两个基因中都有明显增加的罕见变异负担。从软骨肉瘤患者中鉴定出的六个 PALB2 变异中的四个适度影响 HR 功能,11 个 BRCA2 变异中的三个在实验检测中导致功能丧失。这些结果,以及先前关于 Palb2 基因敲除小鼠胚胎中脊索的异常形态和 Brachyury 表达以及与高级软骨肉瘤中 HR 缺陷和 HR 基因突变相关的基因组特征的报道,表明 PALB2 和 BRCA2 种系突变可能增加软骨肉瘤的易感性。我们的数据阐明了软骨肉瘤的病因,并支持先前的发现,即 PARP-1 抑制剂可能是一些软骨肉瘤患者的潜在治疗方法。